Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
Isatuximab, carfilzomib, lenalidomide and dexamethasone for high risk MM ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )
25 Jun 2021
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refract...
Dr Claudio Cerchione - IRCCS, Meldola, Italy
Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )
23 Jun 2021
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hod...
Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA
Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )
22 Jun 2021
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refracto...
Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA
Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )
21 Jun 2021
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previ...
Dr John Byrd - The Ohio State University, Columbus, USA
First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )
21 Jun 2021
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL
Prof John Allan - Weill Cornell Medicine, New York, USA
CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL ( Prof John Allan - Weill Cornell Medicine, New York, USA )
17 Jun 2021
Interim results of a phase II study of blinatumomab plus ponatinib for Philadelp...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia chromosome-positive ALL ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leuka...
Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston...
Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )
17 Jun 2021
EHA 2021: Latest in immunotherapy for R/R multiple myeloma
Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cav...
EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )
17 Jun 2021
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 ex...
Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA
A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
15 Jun 2021
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL
Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlan...
GLOW: Fixed-duration ibrutinib and venetoclax for first-line CLL ( Prof Arnon Kater - Amsterdam University Medical Centre, Amsterdam, The Netherlands )
15 Jun 2021
Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma
Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark
Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma ( Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark )
15 Jun 2021